← Policy & Regulation-Standards & approvals (all topics)
Contract manufacturing - pharma CDMO (qualification & concentration)
What it is
Contract development and manufacturing for pharmaceutical innovators requires regulator-approved facilities, multi-year customer audits and validated processes. China-plus-one sourcing has widened the opportunity
Capacity is fixed and capital-heavy, so utilisation determines margin
Impact on industries
- Regulatory facility qualification is the moat - approved, filed and validated capacity cannot be replicated quickly, so incumbency is durable
- Complex chemistry and biologics carry far better margins than simple intermediates, and are where global innovators most need a second source
- Customer and molecule concentration is severe - a clinical failure or patent expiry removes a revenue line with no substitute demand
- Unfilled capacity is costly against a fixed cost base, and key starting materials remain largely imported from China